Trial Profile
Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs RBM 007 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; First in man
- Acronyms SUSHI
- Sponsors Ribomic
- 05 Dec 2023 According to a Ribomic media release, data from this study were published in the Eye.
- 05 Dec 2023 Results published in a Ribomic Media Release.
- 02 Jul 2019 Status changed from recruiting to completed.